These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 552849)

  • 21. [Interaction of phenylbutazone and tolbutamide in man].
    Szita M; Gachályi B; Tornyossy M; Káldor A
    Orv Hetil; 1979 Nov; 120(47):2843-4. PubMed ID: 394087
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
    Gachályi B; Tornyossy M; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of tolbutamide metabolism by antimalarial drugs.
    Karbwang J; Back DJ; Bunnag D; Breckenridge AM
    Southeast Asian J Trop Med Public Health; 1988 Jun; 19(2):235-41. PubMed ID: 3227403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
    Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits.
    Tterlikkis L; Day JL; Brown DA; Schroeder EC
    Cancer Res; 1983 Apr; 43(4):1675-9. PubMed ID: 6682007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of phenylbutazone and tolbutamide in man.
    Szita M; Gachályi B; Tornyossy M; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):378-80. PubMed ID: 7450929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses.
    van Dijk AJ; Parvizi N; Taverne MA; Fink-Gremmels J
    J Vet Pharmacol Ther; 2008 Dec; 31(6):489-95. PubMed ID: 19000269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers.
    Di Stefano AF; Rusca A; Loprete L; Dröge MJ; Moro L; Assandri A
    Antimicrob Agents Chemother; 2011 May; 55(5):2122-8. PubMed ID: 21402860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoxetine: clinical pharmacology and physiologic disposition.
    Lemberger L; Bergstrom RF; Wolen RL; Farid NA; Enas GG; Aronoff GR
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):14-9. PubMed ID: 3871765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of allopurinol and size of dose on the metabolism of phenylbutazone in patients with gout.
    Horwitz D; Thorgeirsson SS; Mitchell JR
    Eur J Clin Pharmacol; 1977 Oct; 12(2):133-6. PubMed ID: 923626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of phenobarbital on hyperbilirubinemia caused by nicotinic acid and rifamycin--SV in healthy subjects].
    Gentile S; Porcellini M; Leo C; Foglia F
    Boll Soc Ital Biol Sper; 1979 Nov; 55(21):2184-9. PubMed ID: 548051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.
    Robson RA; Miners JO; Whitehead AG; Birkett DJ
    Br J Clin Pharmacol; 1987 Jun; 23(6):772-5. PubMed ID: 3606937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allopurinol influences aminophenazone elimination.
    Barry M; Feely J
    Clin Pharmacokinet; 1990 Aug; 19(2):167-9. PubMed ID: 2379382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of clarithromycin on the pharmacokinetics of tolbutamide.
    Jayasagar G; Dixit AA; Kishan V; Rao YM
    Drug Metabol Drug Interact; 2000; 16(3):207-15. PubMed ID: 11116754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats.
    Sugita O; Sawada Y; Sugiyama Y; Iga T; Hanano M
    Biochem Pharmacol; 1981 Dec; 30(24):3347-54. PubMed ID: 7326045
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol.
    Witten J; Frederiksen PL; Mouridsen HT
    Acta Pharmacol Toxicol (Copenh); 1980 May; 46(5):392-4. PubMed ID: 7376891
    [No Abstract]   [Full Text] [Related]  

  • 38. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.
    Lumholtz B; Siersbaek-Nielsen K; Skovsted L; Kampmann J; Hansen JM
    Clin Pharmacol Ther; 1975 Jun; 17(6):731-4. PubMed ID: 1139863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proceedings: Pharmacokinetic analysis of the dicumarol-tolbutamide interaction in man.
    Jähnchen E; Gilfrich HJ; Groth U; Meinertz T
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R88. PubMed ID: 49859
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rifamycin SV in the treatment of fistulized pyopneumothorax of children].
    CARRATU L
    Arch Tisiol Mal Appar Respir; 1963 Mar; 18():265-8. PubMed ID: 14018868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.